open access

Vol 5, No 5 (2009)
Guidelines / Expert consensus
Published online: 2009-12-01
Get Citation

Soft tissue sarcoma - diagnosis and treatment

Włodzimierz Ruka, Piotr Rutkowski, Maciej Krzakowski, Urszula Grzesiakowska, Konrad Ptaszyński, Arkadiusz Jeziorski, Wojciech Polkowski, Janusz Ryś, Janusz Słuszniak, Wirginiusz Dziewirski, Tadeusz Morysiński, Tomasz Świtaj, Marek Bębenek, Janusz A. Siedlecki, Janusz Limon, Zbigniew I. Nowecki
Onkol. Prak. Klin 2009;5(5):198-210.

open access

Vol 5, No 5 (2009)
EXPERTS' OPINION
Published online: 2009-12-01

Abstract

Significant progress in the treatment of soft tissue sarcoma (STS), both primary tumor and local recurrences/ metastatic disease, has been achieved in recent years. Surgery is essential modality, but the use of combined treatment (standard combination of surgery with adjuvant radiotherapy, chemotherapy in selected cases and perioperative rehabilitation) in highly-experienced centers increased possibility of cure and limitations of extent of local surgery. Current combined therapy together with the use of reconstructive methods allows for limb-sparing surgery in majority of soft tissue sarcoma patients (amputation in 10% of cases as compared to approximately 50% in the 1960-70s). The slow, but constant, increase of rate of soft tissue sarcoma patients with long-term survival has been observed. Contemporary 5-year overall survival rate in patients with extremity soft tissue sarcomas is 55-78%. In case of diagnosis of metastatic disease the prognosis is still poor (survival of approximately 1 year).
Good results of local therapy may be expected only after planned (e.g., after preoperative biopsy - tru-cut or incisional) radical surgical excision of primary tumor with pathologically negative margins (R0 resection). Following appropriate diagnostic check-up, adjuvant radiotherapy is necessary in the majority of patients treated with radical surgery need, as well as long-term rehabilitation and follow-up examinations in treating center are needed for at least 5 years.
The progress is due to the introductionof targeted therapy acting on molecular or genetic cellular disturbances detected during studies on etiopathogenetic mechanisms of sarcoma subtypes. In view of rarity of sarcomas and necessity of multidisciplinary therapy, the crucial issue is that management of these tumors should be hold in experienced oncological sarcoma centers.

Abstract

Significant progress in the treatment of soft tissue sarcoma (STS), both primary tumor and local recurrences/ metastatic disease, has been achieved in recent years. Surgery is essential modality, but the use of combined treatment (standard combination of surgery with adjuvant radiotherapy, chemotherapy in selected cases and perioperative rehabilitation) in highly-experienced centers increased possibility of cure and limitations of extent of local surgery. Current combined therapy together with the use of reconstructive methods allows for limb-sparing surgery in majority of soft tissue sarcoma patients (amputation in 10% of cases as compared to approximately 50% in the 1960-70s). The slow, but constant, increase of rate of soft tissue sarcoma patients with long-term survival has been observed. Contemporary 5-year overall survival rate in patients with extremity soft tissue sarcomas is 55-78%. In case of diagnosis of metastatic disease the prognosis is still poor (survival of approximately 1 year).
Good results of local therapy may be expected only after planned (e.g., after preoperative biopsy - tru-cut or incisional) radical surgical excision of primary tumor with pathologically negative margins (R0 resection). Following appropriate diagnostic check-up, adjuvant radiotherapy is necessary in the majority of patients treated with radical surgery need, as well as long-term rehabilitation and follow-up examinations in treating center are needed for at least 5 years.
The progress is due to the introductionof targeted therapy acting on molecular or genetic cellular disturbances detected during studies on etiopathogenetic mechanisms of sarcoma subtypes. In view of rarity of sarcomas and necessity of multidisciplinary therapy, the crucial issue is that management of these tumors should be hold in experienced oncological sarcoma centers.
Get Citation

Keywords

soft tissue sarcoma; targeted treatment; surgery; radiotherapy

About this article
Title

Soft tissue sarcoma - diagnosis and treatment

Journal

Oncology in Clinical Practice

Issue

Vol 5, No 5 (2009)

Article type

Guidelines / Expert consensus

Pages

198-210

Published online

2009-12-01

Bibliographic record

Onkol. Prak. Klin 2009;5(5):198-210.

Keywords

soft tissue sarcoma
targeted treatment
surgery
radiotherapy

Authors

Włodzimierz Ruka
Piotr Rutkowski
Maciej Krzakowski
Urszula Grzesiakowska
Konrad Ptaszyński
Arkadiusz Jeziorski
Wojciech Polkowski
Janusz Ryś
Janusz Słuszniak
Wirginiusz Dziewirski
Tadeusz Morysiński
Tomasz Świtaj
Marek Bębenek
Janusz A. Siedlecki
Janusz Limon
Zbigniew I. Nowecki

References (16)
  1. Wojciechowska U, Didkowska J, Tarkowski W. Nowotwory złośliwe w Polsce w 2004 roku. Centrum Onkologii — Instytut, Warszawa 2006.
  2. Casali PG, Jost L, Sleijfer S, et al. ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 Suppl 4: iv132–iv136.
  3. Ruka W, Rutkowski P, Kulig J, et al. Zasady postępowania diagnostyczno-terapeutycznego u chorych na nowotwory podścieliskowe przewodu pokarmowego (GIST) w 2008 roku. Nowotwory — J Oncol. 2008; 58: 493–602.
  4. Ruka W. Mięsaki tkanek miękkich. In: Krzakowski M. ed. Onkologia kliniczna. Borgis, Warszawa 2006: 1153–1220.
  5. Pisters PW, Demetri G, O'Sullivan B. Soft-tissue sarcoma. In: Holland JF, Bast RC, Pollock RE. ed. Cancer Medicine. Wyd. 5. . Dekker Inc., Hamilton 2000: 1903–1930.
  6. Rutkowski P, Nowecki ZI. Mięsaki tkanek miękkich u dorosłych — monografia. Medical Tribune 2009.
  7. Brennan M, Singer S, Maki R. Sarcomas of the soft tissues and bone. In: DeVita VT, Hellman S, Rosenberg SA. ed. Cancer: Principles and Practice of Oncology. Wyd. 7. Lippincott Williams & Wilkins, Philadelphia 2005: 1581–1631.
  8. Fletcher CDM, Rydholm A, Singer S, Sundaram M, Coindre JM. Soft tissue tumours: Epidemiology, clinical features, histopathological typing and grading. In: Fletcher CDM, Unni KK, Mertens F. ed. WHO Classification of Tumour. Tumours of Soft Tissue and Bone. IARCPress 2002: 14–15.
  9. Rubin BP, Fletcher CDM, Inwards C, et al. College of American Pathologists. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med. 2006; 130(11): 1616–1629.
  10. Rydholm A, Gustafson P, Alvegård T, et al. Prognostic factors in soft tissue sarcoma. Acta Orthopaedica Scandinavica. 2016; 70(sup285): 50–57.
  11. Kotilingam D, Lev DC, Lazar AJF, et al. Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin. 2006; 56(5): 282–291.
  12. Mccarter MD, Jaques DP, Brennan MF. Randomized clinical trials in soft tissue sarcoma. Surg Oncol Clin N Am. 2002; 11(1): 11–22.
  13. Davis AM, O'Sullivan B, Bell RS, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002; 359(9325): 2235–2241.
  14. Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma in adults. Lancet. 1997; 350: 1647–1654.
  15. ssels R.D., Lindner L.H., Wust P. i wsp. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised prospective trial. J. Clin. Oncol. 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 10009.
  16. Magenau JM, Schuetze SM. New targets for therapy of sarcoma. Curr Opin Oncol. 2008; 20(4): 400–406.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl